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Abstract
Influenza A virus infects 5–20% of the population annually, resulting in ,35,000 deaths and significant morbidity. Current
treatments include vaccines and drugs that target viral proteins. However, both of these approaches have limitations, as
vaccines require yearly development and the rapid evolution of viral proteins gives rise to drug resistance. In consequence
additional intervention strategies, that target host factors required for the viral life cycle, are under investigation. Here we
employed arrayed whole-genome siRNA screening strategies to identify cell-autonomous molecular components that are
subverted to support H1N1 influenza A virus infection of human bronchial epithelial cells. Integration across relevant public
data sets exposed druggable gene products required for epithelial cell infection or required for viral proteins to deflect host
cell suicide checkpoint activation. Pharmacological inhibition of representative targets, RGGT and CHEK1, resulted in
significant protection against infection of human epithelial cells by the A/WS/33 virus. In addition, chemical inhibition of
RGGT partially protected against H5N1 and the 2009 H1N1 pandemic strain. The observations reported here thus contribute
to an expanding body of studies directed at decoding vulnerabilities in the command and control networks specified by
influenza virulence factors.
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Introduction
The Orthomyxoviridae family member influenza A virus is the
causal agent of acute respiratory tract infections suffered annually
by 5–20% of the human population. There is a significant impact
on morbidity, concentrated in people younger than 20 years, with
economic consequences running into the billions of dollars during
large epidemics [1]. In addition, viral infections are associated with
development of chronic asthma and disease exacerbation in both
children and adults. In particular, acute influenza infection can
amplify airway inflammation in asthmatic patients and induce
alterations in epithelial and stromal cell physiology contributing to
allergen sensitization, exaggerated bronchoconstriction, and
remodeling of airway epithelia [2]. Mortality rates associated with
seasonal flu are low, but the aging population is at risk for
development of severe congestive pneumonia which kills ,35,000
people each year in the U.S. [1]. Of continual concern is the threat
of emergent high virulence strains such as the Spanish flu (H1N1),
Asian flu (H2N2) and Hong Kong flu (H3N2) pandemics which
claimed millions of lives world-wide.
Current treatments are focused on vaccines and drugs that
target viral proteins. However, both of these approaches have
limitations as vaccines require yearly development and lag
detection of new strains, while viral proteins have a stunning
capacity to evolve resistance to targeted agents [3]. The genome of
the influenza A virus consists of 8 negative single-strand RNA
segments that encode 11 functional peptides necessary for viral
replication and virulence [1]. Thus the viral-autonomous reper-
toire of gene products is extremely limited and influenza A
replication is dependent upon hijacking host-cell biological systems
to facilitate viral entry, replication, assembly, and budding. The
recognition that a suit of human host proteins are required for IVA
infection and replication presents additional targeting strategies
that may be less prone to deflection by the highly plastic viral
genome.
Here we have employed the cytopathic effects of H1N1
infection in bronchial epithelial cells as a mechanism to isolate
host genes that represent intervention target opportunities by
virtue of their contribution to H1N1 infection and replication, or
by virtue of their contribution to viral virulence factor-dependent
evasion of innate immune responses. A primary whole-genome
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arrayed siRNA screen identified gene depletions that either
deflected or promoted bronchial epithelial cell death upon
exposure to the H1N1 A/WSN/33 influenza virus and were not
cytotoxic to mock infected cells. Integration with orthogonal data
sets, describing host gene function [4–8], parsed collective ‘targets’
into four functional classes. 1) Targets that, when depleted,
enhance bronchial epithelial cell survival upon H1N1 exposure,
and are required for viral replication. This class presumably
represents host factors that facilitate viral infection and/or are
required to support viral replication. 2) Targets that, when
depleted, reduce bronchial epithelial cell survival upon H1N1
exposure, and are required for viral replication. This important
and initially unanticipated class, likely represents proviral host
factors that deflect cell death checkpoint responses that would
otherwise engage upon detection of viral infection. 3) Targets that,
when depleted, reduce bronchial epithelial cell survival upon
H1N1 exposure and enhance viral replication relative to controls.
Recently discovered innate immune pathway components, such as
IFITM3 that are responsive to H1N1 infection, are members of
this class, which presumably represent antiviral restriction factors
that normally oppose infection. 4) Targets, that when depleted,
enhance bronchial epithelial cell survival upon H1N1 exposure
and enhance viral replication as compared to controls. These host
factors are likely responsible for influenza virus-mediated cyto-
pathic effects. Chemical inhibition of gene products from two
classes, RABGGTASE and CHEK1, indicated these targets might
be pharmacologically addressable for H1N1 intervention in an
epithelial cell autonomous context.
Results and Discussion
Influenza A infection is associated with pathological changes
throughout the respiratory tract, however the major site of impact
appears to be the respiratory epithelia. Bronchoscopy of patients
with uncomplicated influenza infections reveals alterations in the
ciliated epithelia of the larynx, trachea, and bronchi that includes
vacuolization, loss of cilia, and desquamation of columnar
epithelial cells and goblet cells down to the basal cell layer.
Importantly, viral antigen is found predominantly in the epithelial
cells and mononuclear cells [1]. Therefore, for the studies
described here, we employed telomerase-immortalized human
bronchial epithelial cells (HBEC30) that retain the capacity to
differentiate into a polarized ciliated epithelial sheet [9]. In
undifferentiated cell culture, we found that 100% of HBEC30 in
culture display viral protein production after a 24-hour exposure
to mouse-adapted virus at an MOI of 5 (Figure 1A, B). This leads
to an approximately 50% decrease in cell viability 48-hours post
infection (Figure 1C). Given these observations, we adopted
a whole genome siRNA screening strategy that involved a 48-hour
incubation post siRNA transfection, followed by a 48 hour
exposure to influenza A/WSN/1933 or carrier, with cell viability
as the endpoint assay. Raw viability values were converted to
viability Z-scores with a metric that normalized for both position
and batch effects (Figure 1D, see methods). The dynamic range of
viability scores observed under screening conditions potentially
affords the opportunity to identify both enhancers and resistors of
viral pathogenicity (Table 1 in Supporting Information S1).
Considering siRNA pools associated with Z-scores that were equal
to or greater than 3 standard deviations above (resistors) or below
(sensitizers) the mean of the population, 53 candidate resistors and
182 candidate sensitizers were identified (Table 2 in Supporting
Information S1). A representative sample of targets was further
tested for consequences on viral protein accumulation and viral
replication. As might be expected, the majority of the siRNA pools
that deflect a viral cytopathic response resulted in reduced viral
protein accumulation, as detected by quantitation of viral proteins
at single cell resolution, and reduced production of infectious
particles (Figure 2A). Among these, IVNS1ABP and the splicing
factor SFPQ directly interact with the viral pathogenicity factor
NS1, presumably reflecting a positive role in support of viral
corruption of host machinery for viral protein production [10]. Of
interest in this class is RRAGD, a small G-protein that supports
the amino-acid responsiveness of mTOR as a component of the
‘‘ragulator’’ [11]. Several reports have highlighted the importance
of viral induction of mTOR for viral replication, but the
mechanism is not fully elaborated [6,12]. Given the participation
of endosomes as a viral entry mechanism [13], it is tempting to
speculate that RRAGD is a limiting host factor for viral corruption
of mTOR regulation. Additional factors in this group are involved
with the host defense response, p53-mediated cell death and
vesicle maturation and trafficking. To test for false positives arising
from off-target effects of siRNA treatment, we retested 88 siRNA
pools as four individual oligos. Approximately 60% of siRNAs
retested with two or more oligos reproducing the original
phenotype (Figure S1).
Among the most potent members of the sensitizer class were the
previously described proviral host factor IFITM3 and its homolog
IFITM1 (Table 7 in Supporting Information S1). IFITM3 has
been reported to be required for restriction of viral infection and is
thought to inhibit viral entry [4,14]. These gene products are
interferon responsive, and depletion was associated with enhanced
viral pathogenicity and enhanced viral protein production at
limiting MOIs (1 and 0.1) as compared to controls (Figure 2A, B,
C). Unexpectedly, cells depleted of IFITM3 produced fewer
infection competent viral particles as determined by secondary
infection of MDCK cells with cell culture supernatants (Figure 2
A, E). For these assays, HBEC30 cell cultures were infected with
an MOI of 5 for 48 hours post transfection with siRNA pools.
Supernatants were collected 24 hours post infection and used to
infect confluent MDCK cell cultures. Notably, we observed
enhanced frequency as well as enhanced amplitude of viral protein
accumulation in IFITM3 depleted cells during primary infection.
Reduced production of infectious particles, in the face of enhance
viral protein production, may therefore be a consequence of either
limiting host factors or disruption of viral protein/host factor
stoichiometry required for assembly of viable viral particles. Of
interest, the viral cytophathic effect was greatly enhanced upon
IFITM3 depletion in the presence or absence of the virulence
factor NS1, a viral protein known to block many of the innate
immunity responses [15–19] (figure 2F, G). However, deletion of
NS1 results in complete failure of infectious particle production
even upon IFITM3 depletion (Figure 2H). These observations
would place IFITM3 function early in the viral life cycle and
independent of NS1 function, consistent with reports that indicate
IFITM3’s antiviral activity is at the level of viral entry [14].
Depletion of the cell cycle/DNA damage checkpoint proteins
CDC2 and CHEK1, like IFITM3, appeared to promote viral
protein production and cytopathic response, while impairing
assembly of infection-competent viral particles. A global compar-
ison of the candidate modulators of H1N1 pathogenicity identified
here with two whole-genome siRNA screens for modulators of cell
cycle progression revealed a significant intersection (Figure 3A).
However, CDC2 and CHEK1 depletion show quite distinct
consequences on G1 versus G2 arrest suggesting their contribution
to H1N1 infection may be independent of cell cycle control.
CHEK1 has not been previously isolated in viral pathogenicity or
viral replication screens, including those performed with the same
siRNA library employed here (Figure 3B, C, Tables 3 and 4 in
Influenza Virus Intervention Target Opportunities
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Supporting Information S1). To investigate additional biological
processes that may be associated with CHEK1 modulation of viral
infection, we assembled a context-specific protein-protein in-
teraction sub-network defined by the genomic Z-score distribution
of the primary screen (Figure S7). This subnetwork revealed the
circadian gene Timeless, recently defined as a master regulator of
the host defense response [20], within the first-degree neighbor-
hood of CHEK1 (Figure 3D). Given this association, we
investigated the consequence of chemical inhibition of CHEK1
on H1N1 infection.
We employed SB218078, an investigational CHEK1 inhibitor
similar to one currently in clinical trials as an anti-neoplastic agent,
with an in vitro IC50 of 0.015 mM and a Ki,app. of 1564 [21,22].
Pretreatment of cultures with 1 uM or 100 nM SB218078 for
12 hours resulted in significant inhibition of viral protein
accumulation together with a marked virus-specific death response
by 24 hours (Figure 4A, B). While some viral infection was
detected at the 100 nM dose, viral protein production was severely
limited at single cell resolution (Figure 4B, C). These observations
suggest that SB218078 is releasing a cell death response to viral
detection that would otherwise be suppressed during the viral
replication cycle. Viral-induced cell death was also observed upon
siRNA-mediated CHEK1 depletion (Figure 2A). The seemingly
contradictory increase in infection frequency upon CHEK1
depletion may therefore be an indirect consequence of infection
of low density residual cell populations with hypomorphic CHEK1
activity. Remarkably, SB218078 had no consequence on H1N1
replication in A549 cells, a cancer cell line often employed to test
for modulators of viral replication and host responses [5,23,24]
(Figure 4E, F). However, a nontransformed, telomerase-immor-
talized bronchial epithelial cell line, derived from a different
patient, HBEC3 [25], was identical to HBEC30 in its re-
Figure 1. Identification of Host Modulators of Influenza Infection. (A) HBEC30 were infected with A/WSN/33/H1/N1 (WSN) at an MOI of 5 and
examined for accumulation of viral proteins by immunoblot at the indicated time-points post-infection. (B) Cells treated as in B were immunostained
for detection of viral protein accumulation at single cell resolution. Top panels labeled WSN show anti-influenza A staining and bottom panels labeled
Hoescht show nuclear staining with Hoescht. (C) Parallel cultures were also examined for consequences on cell viability over a 72-hour time-course.
(D) The rank-ordered Z-score distribution from each of 21,125 siRNA pools targeting the annotated human genome is shown. Dashed lines indicate 3
standard deviations above (red) and below (green) the mean of the distribution.
doi:10.1371/journal.pone.0039284.g001
Influenza Virus Intervention Target Opportunities
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Figure 2. Characterization of Viral Replication Response. (A) A panel of 33 siRNAs was assayed for viral protein accumulation and infectious
particle production. HBEC30s were transfected with siRNA and infected with WSN at an MOI of 5. For primary infection, cells were fixed at indicated
time points and viral protein was detected by immunostaining of viral proteins. Supernatants from infected cells were collected at 24 hours post
infection and used for secondary infection of MDCK cells with viral protein detection by immunostaining (right column, 20). Resistors are shown in the
top panel and sensitizers in the bottom. (B) HBEC30 were transfected with siRNA targeting IFITM3 or control siRNA and infected with WSN at an MOI
of 0.1. Viral protein was detected at 12 hours post infection by immunostaining with anti-influenza antibodies (WSN panels) (Meridian Life Science,
Inc, Cat# B65141G). (C) Cells treated in B were counted and the percent of infected cells was quantified. (D) Cells treated as in B were incubated
48 hours post infection and cell viability was measured. (E) Supernatants from WSN infected HBEC30s were collected 24 hours post infection and
used for secondary infection of MDCK cells with viral protein detection by immunostaining. (F) HBEC30s were transfected with indicated siRNAs and
Influenza Virus Intervention Target Opportunities
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sponsiveness to SB218078 (Figure 4G). These observations
indicate intervention targets may be available in non-tumorigenic
cells that are uncoupled from host regulatory networks in cancer
cells, and potentially explain why CHEK1 was not identified in
other efforts to date that have universally relied on cancer lines as
screen hosts [4–7,26].
infected with WSN lacking the viral protein NS1, cell viability was measured 48 hours post infection. (G) Cells treated as in F were fixed at 24 hours
post infection and immunostained for viral protein for calculation of percentage of infected cells. (H) Supernatants from cells in G were used for
secondary infection in MDCK cells and viral protein was detected by immunostaining. (P values; * ,0.05, ** ,0.01, *** ,0.0001).
doi:10.1371/journal.pone.0039284.g002
Figure 3. Functional Classification of Candidate Hits. (A) siRNA screen results from this study were compared with data from two published
screens for cell cycle modulators and the overlap is shown. (B) Intersection of hits from this study with those examining host modulators of HIV
infection (Table 4 in Supporting Information S1). (C) Cell viability data was queried against four published screens using viral replication as the end-
point assay. Candidate hits were binned into functional classes based upon perturbation of viral cytopathogenicity together with viral replication. (D)
Two pharmacologically addressable Netwalk subnetworks are shown.
doi:10.1371/journal.pone.0039284.g003
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Figure 4. Viral Inhibition by SB218078. (A) HBEC30s were treated with SB218078 at indicated concentrations and cell viability was measured
after 48 hours. (B) HBEC30s were treated as in A and infected with WSN at an MOI of 5 followed by immunostaining at indicated time points. Top
panels labeled WSN show anti-influenza A staining and bottom panels labeled Hoescht show nuclear staining with Hoescht. (C) Fluorescence
Influenza Virus Intervention Target Opportunities
PLoS ONE | www.plosone.org 6 August 2012 | Volume 7 | Issue 8 | e39284
We next queried the behavior of gene depletions identified here
that modulate H1N1 cytopathic effects to those in 4 whole-
genome siRNA screens which measured influenza virus replication
as the end-point assay [4–7]. This allowed us to parse collective
‘hits’ into four functional classes (Figure 3C, Table 5 in Supporting
Information S1). Class 1: genes that, when depleted, enhance
bronchial epithelial cell survival upon H1N1 exposure, and are
required for viral replication. This class presumably represents
host factors that facilitate viral infection and/or are required to
support viral replication. Class 2: genes that, when depleted,
reduce bronchial epithelial cell survival upon H1N1 exposure, and
are required for viral replication. This, initially unanticipated but
very intriguing class, likely represents host factors that deflect cell
death checkpoint responses that would otherwise engage upon
detection of viral infection. Class 3: genes that, when depleted,
reduce bronchial epithelial cell survival upon H1N1 exposure and
enhance viral replication relative to controls. This class pre-
sumably represents antiviral restriction factors that normally
oppose infection. Class 4: genes, that when depleted, enhance
bronchial epithelial cell survival upon H1N1 exposure and
enhance viral replication as compared to controls. Of note,
Class 2, which may represent novel intervention target opportu-
nities, includes TRRAP, a large multidomain protein of the
phosphoinositide 3-kinase-related kinases (PIKK) family that is
a component of many histone acetyltransferase (HAT) complexes.
TRRAP was recently identified as a bona fide oncogene in
melanoma through cancer genome resequencing efforts, however,
its transforming mechanism is unknown [27].
By nature, a challenge to siRNA-screening efforts is false
negatives that derive from weak phenotypes due to suboptimal
depletion of what are otherwise key factors in the biological
process under investigation. One opportunity to help meet this
challenge is to employ coherent behavior of gene sets to identify
key biological processes supporting a phenotype rather than
relying solely on an arbitrary scoring threshold for each individual
gene. We employed Netwalk [28] here to facilitate identification of
such gene sets based on overrepresentation of functionally
coherent subnetworks within the graph (Figures S1, S2, S3, S4,
S5, S6, S7, S8 and S9). One such subnetwork implicated
prenylation of Rab-family GTPases in support of H1N1 replica-
tion (Figure S4 and Figure 3D). To test this we employed 3-
IPEHPC, a specific inhibitor of the type II Geranylgeranyl-
transferases (IC50 of 1.27 mM and a Ki of 0.211 mM for Rab1a
modification [29]). As such, 3-IPEHPC specifically inhibits
modification of Rab-family proteins with a carboxy-terminal CC
motif as opposed to the carboxy-terminal CAAX motif [29].
HBEC-30 cells pretreated with 3-IPEHPC for 24 hours were
significantly refractory to infection by H1N1 (Figure 5A, B).
Inhibitory activity was observed at concentrations as low as
125 nM (Figure 5C). Unlike SB218078, A549 cells were also
responsive to 3-IPEHPC (Figure 5D, E). While the use of a mouse-
adapted virus facilitates large-scale screening and allows compar-
isons with other published screening efforts, the extent to which
results translate to seasonal or highly pathogenic strains is not
established. Importantly, 3-IPEHPC was protective against in-
fection with the avian strain H5/N1 and the recent pandemic
swine flu strain H1/N1 (Figure 5D, E).
A stark limitation of arrayed siRNA screens is the requirement
for ‘‘single gene’’ phenotypic penetrance. This can limit sensitivity
of detection of relevant molecular entities due to insufficient
protein depletion and/or the presence of functionally redundant
gene products. As a mechanism to potentially reveal combinatorial
contributions of gene function to viral replication and cytopathic
effects, we repeated the original screen using a library of 426
human microRNA mimics. These reagents have the advantage of
inducing multigenic perturbations, though accurate assignment of
target space is a significant challenge. This effort identified a small
cohort of miRNA mimics that either enhanced or deflected H1N1-
induced cell death (Figure 6A, B, Table 6 in Supporting
Information S1). 11 of these were further examined for con-
sequences on H1N1 viral protein production in HBEC30 cells,
which identified both sensitizers and resistors that enhanced or
repressed viral replication (Figure 6C). Of note, a test for ‘‘hits’’
that also have activity against the recent pandemic strain Cal/04/
09 identified two miRNA mimics that impair Cal/04/09 protein
production in A549 cells (hsa-miR-495 and hsa-miR-519a,
Figure 6D). To infer biological processes that may be engaged
by the miRNAs that can impair H1N1 replication, we examined
the intersection of predicted miRNA targets and single-gene
perturbations that behaved similarly to the subject miRNA.
Candidate miRNA target genes were selected based on seed
sequence presence in 39 UTRs as defined by Target Scan context
scores. These predictions were intersected with siRNA data from
this study and those of the 4 whole-genome siRNA screens that
measured influenza virus replication [4–7]. When considered as
a heuristic, this analysis produced three subnetworks that may
correspond to the miRNA mode of action, namely the
glycosylphosphatidylinositol transamidase, viral and host protein
ubiquitylation [30,31] and alternative mRNA splicing (Figure 6E).
Here we have focused on isolation of H1N1 pathogenicity
response modifiers in human bronchial airway epithelial cells
(HBEC). This cell type was selected as tissue culture model that
may be enriched for conservation of cell autonomous biological
features representative of the viral target tissue. These cells resist
plaque formation, but are highly sensitive to single cycle infection.
From whole-genome siRNA and miRNA mimic screening, both
candidate sensitizer and resistor response modifiers were identi-
fied. A key deliverable from this analysis was the identification of
gene products that apparently serve to restrain cell death responses
that would otherwise engage upon detection of viral infection.
Though not required to support cell viability in the absence of
viral challenge, depletion of genes in this class enhanced the death
response to H1N1 infection concomitant with restraining H1N1
protein production. As such, this class may represent targets for
interventions that restrain propagation of multi-cycle infection by
facilitating suicide of infected cells prior to production of new
infectious particles. A chemically addressable member of this class,
CHEK1, showed strong activity in multiple HBEC lines but not in
A549, a non-small cell lung tumor derived line commonly
employed to model influenza virus infection. This suggests that
intervention targets may be available in normal epithelial cells that
are uncoupled from host regulatory networks in cancer cells.
intensity was measured and quantified from B. (D) Percentage of infected cells from B. (E) A549 cells were pretreated with 218078 and infected with
WSN at an MOI of 5. Viral protein was detected by immunostaining. Top panels show anti-influenza A staining (WSN) and bottom panels show
nuclear staining (Hoescht). (F) Quantification of percent of infected cells in E. (G) HBEC3-KT cells were pretreated with SB218078, infected with WSN at
an MOI of 5 and immunostained for detection of viral protein. The percentage of infected cells was quantified. (P values; * ,0.05, ** ,0.01, ***
,0.0001).
doi:10.1371/journal.pone.0039284.g004
Influenza Virus Intervention Target Opportunities
PLoS ONE | www.plosone.org 7 August 2012 | Volume 7 | Issue 8 | e39284
Figure 5. Viral Inhibition by 3-IPEHPC. (A) HBEC30s were pretreated with 3-IPEHPC or buffer and infected with WSN at an MOI of 5. Viral protein
was detected by immunostaining. Top panels show anti-influenza A staining (WSN) and bottom panels show nuclear staining (Hoescht). (B) Overall
fluorescence intensity of cells in A was quantified. (C) Quantification of percent of infected cells in A. (D and E) A549 cells were pretreated with 3-
IPEHPC and infected with either avian H5/N1 or the recent H1/N1 pandemic strain. Lysates from infected cells were collected 24 hours post infection
and viral protein was detected by immunoblot. (P values; * ,0.05, ** ,0.01, *** ,0.0001).
doi:10.1371/journal.pone.0039284.g005
Influenza Virus Intervention Target Opportunities
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Figure 6. miRNA Screen. (A) HBEC30s were transfected with miRNA mimics and screened using conditions identical to the siRNA screen. Z-Scores
were calculated for individual oligos and plotted according to rank order. Dashed lines indicate 2 standard deviations above (red) and below (green)
the mean of the distribution. (B) HBEC30s were transfected with selected miRNA mimics, infected with WSN and cell viability phenotype was
measured 48 hours post infection. (C) Cells treated as in B were fixed and immunostained for viral protein 12 hours post infection. (D) A549 cells were
transfected with miRNA mimics and infected with pandemic H1/N1. Cell lysates were collected 24 hours post infection and viral proteins were
detected by immunoblotting. (E) Network analysis of miRNA predicted targets. Node behavior in siRNA screens is indicated. Edges indicate physical
or functional interactions among nodes. (P values; * ,0.05, ** ,0.01, *** ,0.0001).
doi:10.1371/journal.pone.0039284.g006
Influenza Virus Intervention Target Opportunities
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Materials and Methods
RGGT Inhibitor
Racemic 3-IPHPC (2-hydroxy-3-imidazo[1,2-a]pyridine-3-yl-2-
phosphonopropionic acid) was prepared and characterized as
described previously [32,33] and stored at ,0uC and pH $7
[32,33]. The purity was $98%by 1H NMR. The inhibitor was
tested in this work as the racemate [32,33]. It was subsequently
demonstrated that the individual enantiomers have markedly
different IC50 and Ki values for inhibition of Rab1a prenylation,
thus the racemate value obtained here probably represents an
upper limit with respect to the potency of the more active
stereoisomer.
Cell Culture
HBEC30-KT cells were cultured in KSFM (Invitrogen
Cat#17005) with 1% Pen/strep antibiotics as previously described
[34]. MDCK and A549 cells [from ATCC] were grown in
DMEM with 10% FBS.
Plaque Assay
56105 MDCK [from ATCC] and HBEC-30KT cells [34] were
plated in 6 well plates and grown to confluence overnight. Cells
were infected with WSN virus at 10 fold dilutions with a starting
concentration of 108 pfu/ml. Infected cells were allowed to
incubate at 37uC with tilting every 10 minutes. After incubation
liquid was aspirated and 2 ml of agar solution was added to wells
and allowed to solidify for 1 min. Plates were incubated for 48 hrs
at 37uC. Following incubation plates were fixed with formalde-
hyde for 1 hr. Fixative and agar was removed and cells were
stained with crystal violet.
Viral Protein Detection
HBEC30-KT cells [34] were plated in 96 well plates and
incubated overnight. Cells were infected with WSN virus at an
MOI 5. Whole cell lysates were collected at the indicated time
point and separated by 12% SDS-PAGE gel and transferred to
a nitrocellulose membrane. Cultures for immunofluorescence were
fixed with 4% formaldehyde at indicated time point. Viral protein
was detected in both cases with antibodies for pan influenza A
(1:200), M2 (1:500) or NP (1:500) proteins{a-tubulin (cellsignalling
rabbit mAb, cat#2125S), anti-NS1 [35], anti-NP (Abcam, cat#
ab20343)} followed by detection with either HRP conjugated
secondary or staining with Alexa 498 (1:5,000) or Alexa 594
(1:5,000) conjugated secondary antibodies(from Invitrogen). Wells
were imaged with a 20x lens on a BD Pathway 855 microscope.
Imaged cells were segmented using Hoescht staining and distance
from nucleus, aIVA fluorescence intensity was measured, with
Attovision software.
Viral Titers
HBEC30-KT cells were infected with WSN virus and super-
natants were collected at 24 hours post infection. Supernatants
were then added to MDCK cells at 1% final concentration and
MDCKs were fixed 14 hours after supernatant addition and viral
production in MDCK cells was detected immunostaining.
H5N1 and H1N1 Pandemic Virus
A549 cells were infected with either either influenza A/
Vietnam/1203/2004 (H5N1) HALo virus or pandemic influenza
A/Cal/04/09 virus at an MOI of 1 and viral protein was detected
by immunoblot.
siRNA and miRNA Screens
The siRNA screen was performed using the Dharmacon library
targeting 21,125 genes HBEC30 were plated into 96 well plates at
10,000 cells per well and siRNAs were reverse transfected. Each
siRNA pool was transfected in two sets of triplicates for a total of 6
wells for each siRNA, three wells for infection with IVA and three
wells for mock infection, with a concentration of 50 nM for oligos
and 0.1% DharmaFECT 3 reagent. Cells were incubated for
48 hrs after transfection and infected with influenza A/WSN/33
(H1N1) virus at an MOI of 5. Forty-eight hours after infection cell
viability was assayed using CellTiter-Glo, 15 ml of Promega’s
CellTiter-Glo was added to wells on a 96 well plate for a final
concentration of 7.5%. Plates were rocked for two minutes
followed by 10 minutes incubation. Luciferase activity was
measured with a PerkinElmer EnVision reader. The miRNA
mimic screen was performed with the Dharmacon miRNA mimic
library corresponding to 426 human miRNA’s. Screening
conditions were identical to those described above with the
exception of a 72-hour incubation between transfection and
infection.
Data Normalization and Z-Score Calculation
To remove position effects, raw values from each well were
normalized to the median well of their respective row using the
siMacro found at (http://sourceforge.net). To control for
contamination and technical issues the top 5% of outliers with
the highest coefficient of variation among triplicates were
removed. Outliers were defined as wells with the largest distance
among triplicate values. Normalized data was log2 transformed for
proper distribution of sensitizers and resistors and a ratio of
infected over mock infected was obtained. To control for batch
effects, Z-Scores were calculated using batch specific variance
where for each siRNA pool i Zi = xi-mbatch/sbatch, where x is
the raw data to be normalized, m is the mean of the batch
population, and s is the standard deviation of the batch
population.
Functional Class Assignment
Published data sets were obtained from four siRNA screens for
influenza A modulators that used viral replication as an end point
assay [4–7]. Candidate hits in our screen were queried for
behavior as regards viral replication. Hits that modulated viral
replication greater than 1.5 standard deviations were assigned to
functional classes. In cases were hits showed multiple phenotypes
the strongest phenotype was used for classification.
Data set Comparisons
Screening data was compared for overlap with published hit lists
for cell cycle regulators [36,37], host regulators of HIV infection
[38–40], and interferon stimulated genes (ISGs) [41]. Published
hits that correlated with a change in cell viability greater than two
standard deviations were considered as positive hits.
miRNA Predicted Networks
Predicted targets of miRNAs based on seed sequence were
obtained from TargetScan (http://targetscan.org). Network anal-
ysis of predicted hits was completed using Ingenuity IPA (http://
ingenuity.com) and queried for behavior in siRNA screens for
regulators of influenza A infection.
Network Analysis
Z-scores were used as weights for NetWalk analysis [28].
Interactions with 350 highest and 350 lowest Edge Flux values
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were used to construct the networks with high and low z-scores,
respectively. Analyses and graphics were done in the NetWalker
desktop application (Komurov et al, manuscript submitted,
http://research.cchmc.org/netwalker).
Compounds
HBEC30 or A549 cells were plated on 96 well plates overnight.
Media was removed and replaced with media containing
SB218078 (1mM, 100nM 10nM) 3-IPEHPC (12.5mM, 1.25mM,
125nM) DMSO (0.06%) or plain media. Cells were incubated
overnight and then infected with WSN at an MOI of 5. Cells were
fixed with 4% formaldehyde at 8 hours, 12 hours and 24 hours
post infection and stained as described previously. SB218078 was
purchased from Tocris biosciences cat # 2560 and dissolved in
DMSO. 3-IPEHPC was dissolved in PBS.
Supporting Information
Figure S1 Individual siRNA oligo assays. HBEC30 cells
were transfected in triplicate with four individual siRNA oligos
and infected with WSN. Cell viability was measured 48 hours post
infection and a two-tailed Student’s t-test was performed to
determine significance. Green boxes are oligos with a p value less
than 0.05.
(PDF)
Figure S2 Network analysis of siRNA screen results.
Data from siRNA screen results was used for NetWalk analysis.
Nodes are colored based on Z-Score with red for positive and
green for negative, edges are colored based on interactions, PPI:
protein-protein interaction, TF-Target: gene regulation, GO: GO
similarity. Networks analysis was performed with entire data set.
(PDF)
Figure S3 Networks analysis was performed with
resistors all edges.
(PDF)
Figure S4 Networks analysis was performed with
resistors for signaling edges.
(PDF)
Figure S5 Networks analysis was performed with
resistors with gene regulation edges.
(PDF)
Figure S6 Networks analysis was performed with
sensitizers all edges.
(PDF)
Figure S7 Networks analysis was performed with
sensitizers signaling edges.
(PDF)
Figure S8 Networks analysis was performed with
sensitizers gene regulation edges.
(PDF)
Figure S9 Networks analysis was performed with and
sensitizers GO similarity edges.
(PDF)
Supporting Information S1 Supplementary tables.
(XLS)
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